OncoProg AI
Research type
Research Study
Full title
Prognostic value of ploidy and digital tumour-stromal morphometric analyses for guiding chemotherapy treatment for Stage II / III Colon Cancer Patients
IRAS ID
330060
Contact name
David Kerr
Contact email
Sponsor organisation
Oxford Cancer Biomarkers
Duration of Study in the UK
2 years, 2 months, 0 days
Research summary
Following surgery to remove a colorectal cancer, test results, including blood tests, imaging, and pathology tests conducted on tumour cells, are discussed and used to help decide if additional treatment like chemotherapy is needed.In the UK, around 50% of stage II colon cancer patients receive adjuvant chemotherapy. Chemotherapy can help reduce certain cancer types returning, however chemotherapy can have serious side-effects in 20-30% of patients, and approximately 75%-80% of patients do not benefit from chemotherapy.
A new test, called OncoProg, has been developed to give doctors and patients more information on the likelihood of the tumour coming back (recurring). OncoProg analyses slides that have been made using thin slices of your tumour tissue and determines whether the tumour cells DNA content (ploidy) is normal or not. It also looks at the tissue stroma, this plays a role in tumour growth and spread. OncoProg uses software to identify these markers, then produces a report indicating the risk of the tumour returning. The doctor then uses this additional information together with all the other results, to discuss with the patient what the relative benefits of chemotherapy might be. The test may help to determine whether one drug, or more than one drug (combination chemotherapy) is the best option, or the duration of chemotherapy treatment, taking into the account the risks and benefits.
OncoProg is CE marked and has been shown to be accurate in tests involving over 2,000 people. This current study has the aim of seeing how doctors and patients use OncoProg to help determine the best course of treatment, plus determine whether OncoProg will cost the NHS money, or save the NHS money i.e. is economical.REC name
East of England - Cambridge South Research Ethics Committee
REC reference
23/EE/0227
Date of REC Opinion
17 Nov 2023
REC opinion
Further Information Favourable Opinion